Find in Library

Conventionally, endometrial cancers have been risk-stratified as per the clinco-pathological factors. The Cancer Genome Atlas project identified four distinct molecular subtypes within endometrial cancers which further lead to the clinical validation of molecular classification by various research groups. The molecular classification has influenced the risk stratification, thereby impacting adjuvant treatment decisions and prognostication. Molecular classification has paved the precision oncology in gynaecological cancers further strengthening the ongoing advances in targeted therapies and immunotherapy. This review elaborately presents the development of a new molecular classification of endometrial cancers; its evidence-based clinical utility with a brief overview of future perspectives.